Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours

Belinostat is well tolerated in both patient groups and shows some activity in patients with micropapillary (LMP) disease.